T he benchmark for demonstrating the effectiveness of a therapeutic intervention for coronary artery disease is widely accepted as a reduction in mortality or major adverse cardiac outcomes. In medicine, however, many therapies that do not prolong life are routinely practiced and considered appropriate. There has been tremendous interest in research on the comparative effectiveness of clinical practices since Title VIII of the American Recovery and Reinvestment Act of 2009. 1 Over 1 billion of federal funds was authorized to conduct research in clinical outcomes, effectiveness, and appropriateness of health-related services and procedures. Federal support of research in this arena was, in part, intended to control healthcare costs. If a therapy, for example, is found to have no or little benefit then it will not be practiced and cost will be reduced. In reality, the relationship between quality and cost is much more complicated. 2 The interventional cardiology community has been scrutinized for the use of percutaneous coronary intervention (PCI) in stable ischemic heart disease (SIHD). This is largely related to claims of overuse and studies showing no reduction in death or myocardial infarction (MI) when compared with medical therapy alone. The crucial question is what outcomes should be measured to demonstrate the effectiveness of PCI? In patients with acute coronary syndromes, outcomes of death and MI are relevant because of a high short-term risk of these events. Whereas in SIHD the goal of PCI is symptom relief and health status outcomes need to be measured in additional to other clinical outcomes. Presented is the evidence for the effectiveness of PCI according to clinical indication of the procedure.
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PCI to Reduce Major Adverse Cardiac Events
In patients with acute coronary syndromes, there is no dispute about the effectiveness of PCI for reducing major adverse cardiac events. In ST-segment-elevation MI, reperfusion with either primary PCI or thrombolytic therapy reduces mortality when compared with conservative management. Several randomized clinical trials in the balloon angioplasty and stent era compared primary PCI with thrombolytic therapy. A metaanalysis of 23 trials, 12 with stents, showed that compared with thrombolytic therapy primary PCI reduces mortality, reinfarction, and stroke. 3 In high-risk non-ST-segment-elevation MI acute coronary syndromes, a routine invasive strategy including PCI of culprit lesions is more effective for reducing the risk of death or MI than a selective strategy of revascularization only for demonstrable ischemia. 4 There is no direct evidence that PCI can reduce mortality in patients with SIHD, however, there is reason to think that there is the potential. Studies of patients undergoing noninvasive risk stratification show a relationship between ischemia burden and mortality, and a reduced risk of mortality associated with revascularization. In an observational study of 10 627 patients without previous MI or coronary revascularization referred for myocardial perfusion stress, revascularization within 60 days compared with medical therapy was associated with higher survival at a mean of 1.9 years in patients with moderate-to-large inducible ischemia. 5 In particular, those with high-risk features such as older age, female sex, pharmacological stress versus exercise, and diabetes mellitus benefited the most from revascularization. With respect to the degree of ischemic myocardium, modeling predicted the benefit of revascularization during medical therapy in patients with >10%, with a hazard ratio for cardiac death of 0.49. Limitations of the analysis include lack of information on revascularization strategy (PCI or coronary artery bypass grafting [CABG]) and use of optimal medical therapy (OMT). In support of the findings, a large study of patients without known coronary artery disease (CAD) undergoing coronary CT angiography showed similar observations. The Coronary CT Angiography EvaluatioN For Clinical referred for CCTA and followed patients for a median of 2.1 years. Obstructive CAD was defined as ≥50%. High-risk CCTA anatomy was considered 2 vessel CADs with proximal left anterior descending disease, 3 vessel diseases, or left main disease. Outcomes were assessed using a propensity model according to whether patients underwent revascularization. Compared with medical therapy, revascularization was associated with a survival advantage for patients with high-risk CAD (hazard ratio, 0.38), with no difference in survival for patients with non-high-risk CAD. 6 Because of the observational nature of the study, outcomes were not stratified by mode of revascularization but 82.8% of patients had PCI.
If myocardial ischemia is associated with mortality and a reduction in ischemia reduces the risk of mortality then logically PCI, which reduces ischemia, should reduce mortality. So how can we reconcile the findings of randomized controlled trails such as the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
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Measuring the Effectiveness of PCI (COURAGE) trial, which showed no benefit of PCI during OMT for major adverse cardiac outcomes in patients with SIHD? 7 The simplest explanation, supported by the studies above, is that the degree of jeopardized myocardium is the difference. In support of that, the nuclear substudy of the COURAGE trial demonstrated that in patients with moderateto-severe ischemia (>10%), more patients had a significant reduction in ischemic myocardium with PCI compared with OMT. Despite the small number of patients with high ischemic burden, patients with ischemia reduction had a lower unadjusted risk of death or MI; although after adjustment, the benefit was no longer significant. 8 Disappointingly, metaanalyses of PCI versus OMT for SIHD have not been able to demonstrate a reduction in major adverse cardiac outcomes, even when trying to limit the analysis to patients with documented ischemia. 9, 10 The studies, however, were not able to limit analysis to patients that met a threshold of moderate-tolarge ischemia.
There remain many challenges to proving the theory that PCI reduces mortality is SIHD compared with OMT; a speculation I think is true. If the goal is to show a mortality benefit for PCI, then we have not done an adequate job defining the appropriate high-risk population or documenting ischemia reduction. Dating back over a decade, we had evidence that residual ischemia post-PCI as measured by fractional flow reserve (FFR) predicts major adverse cardiac outcomes in follow-up. In a study of 750 patients that had FFR after PCI with angiographic success, >5% of patients had a residual FFR of <0.8 and these patient did poorly. 11 Therefore, even a successful PCI can fail to relieve ischemia, a situation usually attributed to severe diffuse disease. Studies of PCI guided by FFR have also demonstrated that patients with angina or moderate-to-severe angiographic coronary stenosis do not always have hemodynamically significant coronary disease and that PCI outcomes are improved when guided by FFR rather than angiography. [12] [13] [14] Therefore, an optimally designed study would enroll patients with high-risk noninvasive findings, anatomy suitable for complete revascularization with PCI guided by FFR, and be adequately powered for a mortality end point. Although this trial design is not feasible, the ongoing International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial will hopefully yield stronger support for the effectiveness of revascularization (including PCI) for the reduction of death or nonfatal MI in patients with moderate-to-large ischemia (http://www.ischemiatrial.org). Although the study is not designed to compare PCI with CABG, I suspect that the ISCHEMIA trial will find that patients revascularized with CABG have the greatest risk reduction when compared with OMT. This is because relief of ischemia is only part of the equation and patients with high atherosclerotic burden are likely to have vulnerable plaques and nontarget lesion-related events that result in either death or MI; events that cannot be prevented by stenting.
Despite the lack of definitive evidence that PCI can reduce mortality in SIHD, the American College of Cardiology/ American Heart Association guidelines state that PCI to improve survival is reasonable in 2 clinical situations, as an alternative to CABG in selected patients with significant unprotected left main disease and in survivors of sudden cardiac death with presumed ischemia-mediated ventricular arrhythmia. In these situations, the amount of ischemic myocardium or clinical consequences of ischemia justify the recommendation. 15 
PCI to Relieve Angina and Improved Health Status
In interventional cardiology, we collect a wealth of data in clinical trials and quality improvement registries and are guided by standard definitions. 16 Clinical success of PCI, for example, is defined as procedural success along with relief of signs or symptoms of myocardial ischemia. 15 Historically, we have not done an adequate job of quantify health-related outcomes in clinical practice and the majority of studies. A review of the data we have on the effectiveness of PCI for these end points can clarify the optimal measures to follow longitudinally.
PCI has a class I indication for relief of angina in patients on guideline-driven medical therapy that have ≥1 significant coronary stenosis. 15 These recommendations are based on multiple studies showing the effectiveness of PCI for reducing angina and improving health status of patients with SIHD. Improvements have been demonstrated in observational registries of PCI and randomized trials comparing PCI with other therapies, such as OMT or CABG. The cumulative data have recently been reviewed in a consensus statement from the Society for Cardiovascular Angiography and Interventions on the effect of PCI on quality of life (QOL). 17 In general, PCI is more effective than medical therapy for relieving angina, prolonging exercise time, and improving QOL. The benefit, however, is dependent on many factors, such as angina severity at baseline, completeness of revascularization, and comorbidities. In addition, the benefit may wane over time because of a variety of reasons such as disease progression, restenosis, and use of PCI in the comparator arm of trials. Another problem with interpreting previous data are that different methods for assessing angina severity and QOL have been used.
There are many qualitative measures of angina severity, such as frequency of nitroglycerine use, number of antianginal medications, or a physician assessment of symptoms such as the Canadian Cardiovascular Society classification. More quantitative measures of functional status include exercise electrocardiogram testing, which can track improvements in exercise time. But the number of seconds more a patient can walk on a treadmill before developing angina may not translate into how much benefit the patient perceives. Patient-reported health status measures, therefore, should be the mainstay of assessing the response to a therapy that is done to improve QOL, such as PCI for SIHD.
There are at least 14 instruments that have been used to evaluate health status and QOL in patients with CAD. Several are specifically designed for patients with ischemic heart disease and can comprehensively measure the domains, which encompass QOL. 17 The Seattle angina questionnaire is an example of a validated instrument well suited for PCI. The relatively brief, 19-item, self-administered questionnaire covers 5 domains of CAD (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception). 18 The prognostic value of these measures should not be minimized. Lower Seattle angina questionnaire scores on some domains are independently associated with outcomes, such as mortality and admissions for acute coronary syndromes. 19 
Recommendations
As interventionalist, we know the effectiveness of PCI for both improving and saving lives from the experience in our day-today practice. Therefore, we may not see the need to quantify the health-related outcomes. There are also obstacles to data collection, which require resources and time. There needs to be support from hospitals to fund the data collection and from registries such as the National Cardiovascular Data Registry to develop modules that collect QOL outcomes. Once the pieces are in place, we can truly understand the effectiveness of PCI for SIHD in the community.
